Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of cusatuzumab plus azacitidine in newly diagnosed AML patients unfit for intensive chemotherapy
MOH_2019-10-24_007385Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cusatuzumab and azacitidine in acute myeloid leukemia (AML) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Efficacy / response rate. Started Jun 2019; status: completed.
02
Drugs
cusatuzumabazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2019-10-24_007385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-10-24_007385.